BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 27018242)

  • 41. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
    Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K
    Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
    Morschhauser F; Fowler NH; Feugier P; Bouabdallah R; Tilly H; Palomba ML; Fruchart C; Libby EN; Casasnovas RO; Flinn IW; Haioun C; Maisonneuve H; Ysebaert L; Bartlett NL; Bouabdallah K; Brice P; Ribrag V; Daguindau N; Le Gouill S; Pica GM; Martin Garcia-Sancho A; López-Guillermo A; Larouche JF; Ando K; Gomes da Silva M; André M; Zachée P; Sehn LH; Tobinai K; Cartron G; Liu D; Wang J; Xerri L; Salles GA;
    N Engl J Med; 2018 Sep; 379(10):934-947. PubMed ID: 30184451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
    Kirschey S; Flohr T; Wolf HH; Frickhofen N; Gramatzki M; Link H; Basara N; Peter N; Meyer RG; Schmitz N; Weidmann E; Banat A; Schulz A; Kolbe K; Derigs G; Theobald M; Hess G
    Br J Haematol; 2015 Mar; 168(6):824-34. PubMed ID: 25546611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
    Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
    Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
    Jain N; Balakrishnan K; Ferrajoli A; O'Brien SM; Burger JA; Kadia TM; Cortes JE; Ayres ML; Tambaro FP; Keating MJ; Gandhi V; Wierda WG
    Oncotarget; 2017 Mar; 8(13):22104-22112. PubMed ID: 27655665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
    Armand P; Redd R; Bsat J; Mayuram S; Giardino A; Fisher DC; LaCasce AS; Jacobson C; Davids MS; Brown JR; Weng L; Wilkins J; Faham M; Freedman AS; Joyce R; Jacobsen ED
    Br J Haematol; 2016 Apr; 173(1):89-95. PubMed ID: 26729345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Ohmachi K; Niitsu N; Uchida T; Kim SJ; Ando K; Takahashi N; Takahashi N; Uike N; Eom HS; Chae YS; Terauchi T; Tateishi U; Tatsumi M; Kim WS; Tobinai K; Suh C; Ogura M
    J Clin Oncol; 2013 Jun; 31(17):2103-9. PubMed ID: 23650408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
    Zinzani PL; Pellegrini C; Gandolfi L; Stefoni V; Quirini F; Derenzini E; Broccoli A; Argnani L; Pileri S; Baccarani M
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):462-6. PubMed ID: 21859554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20.
    Alrifai T; Grant Szymanski K; Venugopal P; Mahon B; Okwuosa T; Karmali R
    Chemotherapy; 2017; 62(2):140-146. PubMed ID: 27960150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
    Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
    Matsumoto Y; Kobayashi T; Shimura Y; Kawata E; Nagoshi H; Ohshiro M; Sugitani M; Shimura K; Iwai T; Fuchida SI; Yoshida M; Kiyota M; Mizutani S; Chinen Y; Takimoto-Shimomura T; Nakao M; Kaneko H; Uchiyama H; Uoshima N; Nishigaki H; Kobayashi Y; Horiike S; Shimazaki C; Taniwaki M; Kuroda J;
    Int J Hematol; 2019 Jul; 110(1):77-85. PubMed ID: 31127456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
    Soumerai JD; Zelenetz AD; Moskowitz CH; Palomba ML; Hamlin PA; Noy A; Straus DJ; Moskowitz AJ; Younes A; Matasar MJ; Horwitz SM; Portlock CS; Konner JA; Gounder MM; Hyman DM; Voss MH; Fury MG; Gajria D; Carvajal RD; Ho AL; Beumer JH; Kiesel B; Zhang Z; Chen A; Little RF; Jarjies C; Dang TO; France F; Mishra N; Gerecitano JF
    Clin Cancer Res; 2017 Aug; 23(15):4119-4126. PubMed ID: 28314788
    [No Abstract]   [Full Text] [Related]  

  • 53. Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
    Beck J; Schwarzer A; Gläser D; Mügge LO; Uhlig J; Heyn S; Kragl B; Mohren M; Hoffmann FA; Lange T; Schliwa T; Zehrfeld T; Becker C; Kreibich U; Winkelmann C; Edelmann T; Andrea M; Bill M; Jentzsch M; Schwind S; Niederwieser D; Pönisch W
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2545-2553. PubMed ID: 28828689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
    Chavez JC; Piris-Villaespesa M; Dalia S; Powers J; Turba E; Nodzon L; Komrokji R; Sokol L; Locke FL; Lancet J; Sotomayor EM; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Res; 2016 Aug; 47():78-83. PubMed ID: 27285853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
    Tisi MC; Paolini R; Piazza F; Ravelli E; Tecchio C; Sartori R; Famengo B; D'Amore ESG; Carli G; Perbellini O; Di Bona E; Ruggeri M; Visco C
    Am J Hematol; 2018 Dec; 93(12):E386-E389. PubMed ID: 30184246
    [No Abstract]   [Full Text] [Related]  

  • 56. A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
    Evens AM; Hong F; Habermann TM; Advani RH; Gascoyne RD; Witzig TE; Quon A; Ranheim EA; Ansell SM; Cheema PS; Dy PA; O'Brien TE; Winter JN; Cescon TP; Chang JE; Kahl BS
    Clin Cancer Res; 2020 Sep; 26(17):4468-4477. PubMed ID: 32532790
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL).
    Kim T; Choi HY; Lee HS; Jung SH; Ahn JS; Kim HJ; Lee JJ; Yoo HD; Yang DH
    BMC Cancer; 2018 Jul; 18(1):729. PubMed ID: 29986691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
    Witzig TE; Johnston PB; LaPlant BR; Kurtin PJ; Pederson LD; Moore DF; Nabbout NH; Nikcevich DA; Rowland KM; Grothey A
    Am J Hematol; 2017 Oct; 92(10):1004-1010. PubMed ID: 28614905
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
    Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
    Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
    Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
    N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.